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Background: Introduction of new vaccines in low- and lower middle-income countries has accelerated
since Gavi, the Vaccine Alliance was established in 2000. This study sought to (i) estimate the costs of
introducing pneumococcal conjugate vaccine, rotavirus vaccine and a second dose of measles vaccine
in Zambia; and (ii) assess affordability of the new vaccines in relation to Gavi’s co-financing and eligibility
policies.
Methods: Data on ‘one-time’ costs of cold storage expansions, training and social mobilisation were
collected from the government and development partners. A detailed economic cost study of routine
immunisation based on a representative sample of 51 health facilities provided information on labour
and vaccine transport costs. Gavi co-financing payments and immunisation programme costs were
projected until 2022 when Zambia is expected to transition from Gavi support. The ability of Zambia
to self-finance both new and traditional vaccines was assessed by comparing these with projected
government health expenditures.
Results: ‘One-time’ costs of introducing the three vaccines amounted to US$ 0.28 per capita. The new
vaccines increased annual immunisation programme costs by 38%, resulting in economic cost per fully
immunised child of US$ 102. Co-financing payments on average increased by 10% during 2008–2017,
but must increase 49% annually between 2017 and 2022. In 2014, the government spent approximately
6% of its health expenditures on immunisation. Assuming no real budget increases, immunisation would
account for around 10% in 2022. Vaccines represented 1% of government, non-personnel expenditures for
health in 2014, and would be 6% in 2022, assuming no real budget increases.
Conclusion: While the introduction of new vaccines is justified by expected positive health impacts, long-
term affordability will be challenging in light of the current economic climate in Zambia. The government
needs to both allocate more resources to the health sector and seek efficiency gains within service
provision.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Gavi, the Vaccine Alliance was founded in 2000 and is now the
largest external funding source for vaccines in low- and lower
middle-income countries [1]. Introducing new vaccines requires
substantial investments, not only in vaccine supplies, but also in
‘systems costs’, such as cold chain expansions [2,3]. Cost estimates
of new vaccine introduction are vital both to Gavi and to recipient
countries [4].
Zambia has introduced four new vaccines with Gavi support.
The combined diphteria-tetanus-pertussis (DTP)-Haemophilus
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influenzae type B (Hib) vaccine was introduced in 2004. This was
switched to DTP-hepatitis B-Hib (‘pentavalent’) vaccine in 2005.
In 2009, a proposal was submitted for pneumococcal conjugate
vaccine (PCV), rotavirus vaccine (RV) and a second dose of
measles (MSD). Gavi approved PCV and MSD in 2010 and RV in
2011, following evidence of plans for cold chain expansions.
However, PCV and MSD were only introduced in July 2013 and
RV in November 2013. Delays were due to a measles outbreak
in 2012, relocation of the Child Health Unit from the Ministry
of Health to the new Ministry of Community Development,
Mother and Child Health in 2011, delays in receiving the Gavi
vaccine introduction grant, and delays in disbursements to sub-
national levels [5].
A comprehensive study on the economic and fiscal costs of
Zambia’s routine immunisation services was undertaken in
2012–13, before introduction of the three new vaccines [6]. This
was part of the multi-country ‘Expanded Programme on
Immunisation Costing (EPIC)” studies, which used a common,
ingredients-based costing approach [7]. The study found that
average costs per vaccine dose delivered totalled US$ 7.18, with
markedly higher unit costs in rural than urban facilities.
Our study objectives were to estimate the incremental costs of
introducing PCV, MSD and RV and evaluate affordability after ces-
sation of Gavi support. Although ‘one-time’ vaccine introduction
costs were calculated, the primary objective was to examine the
longer-term economic costs.
1.1. Gavi eligibility criteria and co-financing policy
Gavi’s current eligibility criteria, established in 2011, is Gross
National Income (GNI) per capita of less than US$ 1500, which is
adjusted annually for inflation to remain constant in real terms.
In 2015, the threshold was US$ 1580 [8]. If GNI per capita increases
above the threshold, the recipient country starts transitioning out
of support [1].
Gavi’s co-financing policy requires countries to co-procure a
portion of their new vaccines and injection equipment. MSD is
exempted from co-financing, but after five years countries must
take on the full costs [9]. Countries are divided into groups accord-
ing to GNI per capita, which serves as a proxy for ability to pay [10]
(Table 1). The trajectory towards self-financing is achieved by
annual increases in co-financing levels in the highest income
groups. The ability of countries to shoulder the increasing financ-
ing requirements has been questioned and shown to vary substan-
tially [11,12].
2. Methods
2.1. Incremental, economic costs of vaccine introductions
Economic costs were estimated in 2014 values, using an
exchange rate of 6.18 Zambian Kwacha for one US$ [13] and
adjusting earlier data by the Zambian Gross Domestic Product
(GDP) deflator [14]. Economic costs were divided into ‘one-time’
and recurring. ‘One-time’ costs were expenditures specifically
undertaken in preparation for the new vaccine introductions.
Recurring costs were those that occur annually in the future.
Capital costs were annualised using a 3% discount rate [15], but
also presented without annualisation to show needed up-front
expenditures.
The number of fully immunised children was approximated by
the number reported to receive three doses of pentavalent vaccine
(penta3). With 602,000 surviving infants and 86% penta3 coverage
in 2014, this was 517,720 children [16]. Costs per capita were esti-
mated using a 2014 population of 15,023,315 [17].
2.1.1. Vaccine and injection supplies
Vaccine costs were calculated by multiplying price per dose,
coverage rate of the first dose, target population size, number of
doses per child in the schedule and the vaccine wastage factor
[18]. UNICEF 2014 vaccine dose prices were US$ 2.10 for RV, US$
0.252 for MSD and US$ 7.00/3.50 for PCV [19]. According to the
Advance Market Commitment for PCV, a certain quantity of doses
is purchased for US$ 7.00 per dose and the remaining at the ‘‘tail
price” of US$ 3.50 [20]. Since co-financing calculations are based
on the tail price and as this will be the price Zambia will pay after
Gavi transition, we used this price [21]. Freight charges for
importing vaccines were 3%, 5% and 14% of the procurement value
for PCV, RV and MSD, respectively [9]. 2014 vaccine coverage rates
of the first doses of PCV and RV were assumed similar to DTP1 at
96% while coverage of MSD was 33% [16]. Vaccine wastage rates
were assumed as 5% for both PCV and RV and 40% for MSD [22].
2.1.2. Cold storage equipment
Cold storage expansions were undertaken at national, provin-
cial, district and health facility levels [23]. Several development
partners contributed to this investment [2]. A proportion of the
investments was allocated to the three new vaccines based on their
relative packed volumes in the new schedule; 4.8 cm3 per dose for
PCV, 17.1 cm3 for RV and 2.13 cm3 for measles [19,24]. The WHO
vaccine volume calculator showed that the new vaccines increased
the required volume by 70%, from 81.3 cm3 to 138 cm3 per penta3
Table 1
Gavi co-financing policies 2008–2017.
2008–2011 2012–2016 2017–
Country groups 1. Fragile
2. Poorest
3. Intermediate
4. Least poor
1. Low-income
2. Intermediate
3. Graduating
1. Initial self-financing
2. Preparatory transition
3. Accelerated transition
Initial co-financing
levels per vaccine
dose
▪ US$ 0.10 – US$ 0.30
▪ Amounts differed for first and
subsequent approved vaccines
US$ 0.20 US$ 0.20
Annual increase in
co-financing per dose
15% for the least poor group 15% for the intermediate group 15% for the preparatory transition group
Trajectory for
transitioning out of
support
None specified Graduating group:
▪ Linear increase to reach full vaccine
price after 5 years
Accelerated transition group:
▪ Linear increase to reach full vaccine price after
5 years
Co-financing linked to
vaccine price
No link Graduating group:
▪ Paying linearly towards full vaccine
price
Preparatory transition group:
▪ Co-financing for individual vaccine differ according to
vaccine prices
Accelerated transition group:
▪ Paying linearly towards full vaccine price
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child [25]. The new vaccines occupied 41% of total vaccine volume;
PCV took up 11%, RV 25% and MSD 5%.
Power consumption for equipment was collected from WHO
Product Information Sheets [26]. A unit price of US$ 0.089 per
kilowatt per hour was obtained from ZESCO, the parastatal
electricity company. Annual maintenance costs of cold storage
equipment were estimated as 10% of the purchase price, based
on a UNICEF maintenance grant.
2.1.3. Transport
The EPIC study found that annualised costs of vehicles, vehicle
maintenance and fuel comprised 12.5% of total immunisation pro-
gramme costs, amounting to US$ 4.35 million in 2014 values, or
US$ 8.39 per penta3 child [6]. Vaccine delivery comprised a
weighted average of 31% of total transport costs (35% in rural
and 13% in urban facilities). Hence, vaccine transport costs
amounted to US$ 2.60 per penta3 child. We increased the vaccine
transport costs by 70%, in line with the increased vaccine volumes
(43% due to RV; 18% to PCV; 9% to MSD), amounting to an incre-
mental cost per penta3 child of US$ 1.82.
2.1.4. Training, social mobilisation and communications
As PCV and MSD were introduced concurrently, training and
social mobilisation were done at the same time. Based on advice
from key informants, we allocated 80% of these costs to PCV and
20% to MSD. Costs were annualised over two years, reflecting the
usual frequency of training.
New vaccination cards and health facility registers were
printed, the Health Management Information System was modi-
fied, and a post introduction evaluation was conducted in July
2014 [27]. These costs were equally distributed between the three
vaccines. For PCV, temperature monitoring log sheets and stickers
instructing health workers to dispose of unused, opened vials were
applied to health facility refrigerators. These investments were all
annualised using a useful life of ten years.
2.1.5. Human resources
Introduction of new vaccines did not lead to additional employ-
ments, but staff opportunity costs need to be accounted for. In the
EPIC study, clinical staff at 51 randomly selected health facilities in
nine districts were asked to allocate their working hours among all
activities during one month [6]. Costs per dose delivered were esti-
mated by dividing staff immunisation costs by number of vaccine
doses delivered per year. Weighted average staff cost per dose
was US$ 1.77, ranging from US$ 0.96 in urban to US$ 4.59 in rural
facilities [6].
The EPIC study took place before introduction of the new vacci-
nes, but facility staff were asked if they thought introductions
would impact operating costs, and 73% responded that they did
not think so [6]. However, in the Post Introduction Survey, 17 out
of 26 health workers said that the new vaccines had increased their
workload [27]. In the absence of time-motion studies, we allocated
half of the EPIC study staff cost per dose to RV and PCV (US$ 0.885),
as these are delivered at the same time as pentavalent vaccine.
However, as MSD requires an additional visit at 18 months, we
allocated the full economic cost of US$ 1.77 to each MSD dose
delivered [6].
2.2. Affordability of Gavi supported vaccines
Zambia’s co-financing contributions were provided by the Gavi
secretariat, and the Gavi website gave values of its vaccine and
injection supplies donations [28]. Predictions of GNI per capita
were used to determine when Zambia enters the accelerated tran-
sition phase [29]. Future co-financing amounts were calculated by
assuming constant prices per dose of all four Gavi supported vacci-
nes and using data from the United Nations Population Division to
predict numbers of surviving infants [30]. Vaccination coverage
was assumed constant for PCV and RV, and assumed to increase
by 5% per year for MSD. Future costs of the remaining vaccines
in the schedule were estimated similarly.
Total government immunisation programme costs were the
sum of systems costs, procurement of traditional vaccines and
injection supplies, and government expenditure to co-procure vac-
cines for Gavi co-financing. The EPIC study found that immunisa-
tion systems costs amounted to US$ 31.8 million in 2011,
equivalent to US$ 61 per penta3 child [6]. Government immunisa-
tion costs for 2014 and beyond were determined by adding the
incremental systems costs of the new vaccine introductions to this
estimate and increasing costs in proportion with the rising birth
cohort and, for MSD, also increased coverage.
When assessing affordability, we compared immunisation pro-
gramme costs with total government health expenditures. For
2008–2014, government health expenditures were collected from
the Accountant General’s Office [31]. For 2015, the health sector
budget was used, and for 2016 and 2017, the mid-term expendi-
ture framework Green Paper [32,33]. As the Zambian government
considers staff costs fixed, we used government health expendi-
tures excluding personnel costs when evaluating the affordability
of vaccines only.
For 2018–2022, we assumed a nominal growth in health care
expenditures of 10% per year, which was the average increase
during 2014–2016, and equivalent to 5% real, annual increase
with predicted inflation rates of around 5% [29]. We also consid-
ered a scenario assuming 0% real increase in annual health
expenditures.
3. Results
3.1. Incremental costs of new vaccine introductions
3.1.1. Financial costs
‘One-time’, non-annualised, incremental costs amounted to US$
4.21 million, equivalent to costs per infant in the birth cohort of US
Table 2
Financial costs of new vaccine introduction in Zambia (2014 US$).
MSD PCV RV Total Percent of total
Cold storage investments 228,515 505,663 1,207,044 1,941,223 46%
Social mobilisation 60,962 243,849 377,190 682,001 16%
Training 40,398 161,591 386,824 588,813 14%
Tally sheets and under-5 cards 157,773 157,773 157,773 473,320 11%
Post introduction evaluation 94,778 94,778 94,778 284,335 7%
Monitoring tools 32,876 131,505 76,918 241,300 6%
Total 615,304 1,295,161 2,300,528 4,210,992 100%
Costs per infant in birth cohort 0.96 2.02 3.58 6.56
Costs per capita 0.04 0.09 0.15 0.28
MSD: Measles second dose, PCV: Pneumococcal conjugate vaccine, RV: Rotavirus vaccine.
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$ 0.96 for MSD, US$ 2.02 for PCV and US$ 3.58 for RV (Table 2). Cold
storage rehabilitation and expansion totalled US$ 4.73 million, of
which US$ 3.04 million was spent on health facility refrigerators
and US$ 1.20 million on national and provincial walk-in cold
rooms. Based on the volume estimates, US$ 1.94 million of the total
was allocated to the three new vaccines (Table 2). Cold storage
investments accounted for 46% of total ‘one-time’ costs while
social mobilisation and training accounted for 16% and 14%,
respectively.
Cold storage expansions were financed by JICA (36%), ELMA
Foundation (34%), Zambian government (10%), Canadian
International Development Agency (9%), ARK (7%), WHO (4%),
and Boston University (0.3%). Gavi, through the vaccine introduc-
tion grant, funded 64% of the social mobilisation, training and
monitoring activities. The remainder was paid by the government
(29%), GSK (3%), WHO (3%) and Absolute Returns for Kids (1%).
3.1.2. Annualised incremental costs
Annual costs of vaccines and injection equipment increased
from US$ 6.8 million to US$ 7.0 million after introduction of MSD,
to US$ 14.0 million after PCV, and to US$ 16.9 million after RV
(Table 3). Compared to the old schedule, the corresponding
increases in vaccine costs were 2% after MSD, 103% after PCV and
147% after all three vaccines were introduced. Vaccine costs per
penta3 child were US$ 13 under the old schedule and US$ 33 after
the three new vaccine introductions.
When ‘one-time’ costs were annualised, training and social
mobilisation were the most important capital costs, each compris-
ing 2% of total costs (Table 4). Cold storage investment only com-
prised 1% of total vaccine introduction costs after annualisation.
The 70% increase in vaccine volume caused extra vaccine transport
costs of US$ 941,715 per year. Incremental staff time opportunity
costs were US$ 351,628 for MSD, US$ 1.38 million for PCV, and
US$ 900,381 for RV.
The EPIC study concluded that economic costs of routine immu-
nisation in Zambia totalled US$ 38.2 million in 2011, equivalent to
US$ 66 per penta3 child [6]. The three new vaccines increased total
economic costs by an estimated 38% to US$ 52.9 million in 2014,
corresponding to US$ 102 per penta3 child. Incremental, annual
systems costs of introducing the three new vaccines were US$
4.9 million, equivalent to US$ 7.69 per child in the birth cohort
and US$ 0.31 per capita. The systems costs per vaccine dose
administered were US$ 1.33 for PCV, US$ 2.15 for RV and US$
3.43 for MSD.
Table 3
Vaccine and injection supplies costs with and without measles second dose, pneumococcal, and rotavirus vaccines (2014 US$).
Antigen Doses per
person
Vaccine coverage of
first dose
Vial
size
Wastage in
percent
Costs per dose
(incl. freight)
Total
vaccine
costs
Injection
supply costs
Total costs % of
total
Bacille Calmette Guerin 1 95% 20 50% 0.15 185,495 52,669 238,164 1%
Diphteria-Tetanus-
Pertussis-HepB-Hib
3 96% 1 5% 2.87 5,242,890 120,314 5,363,205 32%
Measles 1 85% 10 40% 0.29 245,002 40,073 285,075 2%
Oral polio vaccine 4 96% 10 25% 0.23 701,364 – 701,364 4%
Tetanus toxoid 2 74% 10 25% 0.12 172,084 77,881 249,966 1%
Total before new
vaccines
6,546,835 290,937 6,837,773
Measles 2nd dose 1 33% 10 40% 0.29 97,564 15,558 115,567 1%
Pneumococcal conjugate 3 96% 2 5% 3.61 6,766,366 120,314 7,073,884 42%
Rotavirus 2 96% 1 5% 2.21 2,757,647 – 2,832,528 17%
Total with new vaccines 16,168,412 411,252 16,859,752 100%
Table 4
Annualised costs of new vaccine introduction in Zambia (2014 US$).
Measles 2nd dose Pneumococcal Rotavirus Total
Annualised one-time costs:
Training 21,112 84,449 202,158 307,720
Social mobilisation 21,552 107,760 133,348 262,660
Cold storage investments 25,900 55,592 132,702 214,194
Tally sheets and under-5 cards 55,778 55,778 55,778 167,333
Monitoring tools 23,603 58,114 27,193 108,909
Post introduction evaluation 33,507 33,507 33,507 100,521
Sub total 181,451 395,200 584,686 1,161,337
Recurring costs:
Vaccines 97,564 6,766,366 2,757,647 9,621,577
Human resources 351,628 1,382,538 900,381 2,634,548
Vaccine transport 124,758 241,200 575,757 941,715
Cold storage 23,248 52,172 124,538 199,958
Injection supplies 15,558 120,314 – 135,872
Sub total 612,755 8,562,591 4,358,323 13,533,670
Total annualised costs 794,206 8,957,792 4,943,009 14,695,007
2014 reported last dose coverage 33% 77% 73% NA
Children reached with last dose 198,660 463,540 439,460 NA
Cost per child reached with last dose 4.00 19.32 11.25 NA
Costs per dose delivered 4.00 5.17 4.28 NA
Costs per infant in birth cohort 1.24 13.95 7.70 22.89
Costs per capita 0.05 0.60 0.33 0.98
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3.2. Affordability
3.2.1. Co-financing of new vaccines
Zambia introduced pentavalent vaccine in 2005. Gavi’s first co-
financing policy required countries to start co-procuring six years
after introducing the first new vaccine; thus 2011 for Zambia. With
GNI per capita of US$ 490 in 2005, Zambia belonged to the poorest
co-financing country group, entailing flat levels of US$ 0.20 per
dose for the first vaccine [10]. However, Zambia started voluntary
co-financing in 2008 and paid US$ 0.82, US$ 0.92, US$ 0.30 and US$
0.35 per dose of pentavalent vaccine during 2008–2011, respec-
tively. This meant that the government procured 17% of pentava-
lent vaccines during those four years.
When Gavi’s second co-financing policy came into effect in
2012, Zambia’s GNI had increased to US$ 1,650 per capita, placing
it in the intermediate group, requiring a 15% annual increase in the
per dose amount. During 2012, Zambia procured the equivalent of
US$ 0.27 per dose in co-financing for pentavalent vaccine and US$
0.20 for PCV. During 2013, co-financing of RV was added, starting
at US$ 0.20 per dose. During 2015, approximately 12% of pentava-
lent vaccines, 8% of PCV and 9% of RV were co-financed.
Gavi’s new co-financing policy starts in 2016, but the first year
is a grace year with the old policy still applying. Zambia is in the
accelerated transition group, as its GNI per capita has exceeded
the Gavi eligibility threshold for three consecutive years (US$
1650 in 2012, US$ 1700 in 2013 and US$ 1680 in 2014). Hence,
Zambia is predicted to fully finance all vaccines in 2022.
Fig. 1 shows historical and predicted co-financing for the four
new vaccines. Co-financing was US$ 1.7 million in 2015 and will
increase to the full costs of the vaccines of US$ 18.3 million in
2022. While co-financing on average increased by 10% per year
during 2008–2017, it needs to increase by an annual average of
49% between 2017 and 2022. During 2008–2021, vaccines totalling
US$ 54.5 million will need to be co-procured, with pentavalent
vaccine comprising 42%, PCV 39%, RV 16% and MSD 2%. Total vac-
cine costs according to financing source between 2008 and 2022
are included in Table A1 in supplementary material.
3.2.2. Affordability assessment
During 2008–2016, per capita government health expenditures
fluctuated between US$ 14 in 2009 and US$ 45 in 2013 (Fig. 2).
Between 2009 and 2014, the government increased its real health
expenditures (in Kwacha) by an average of 27% per year, but in
2014 and 2015 there was a real decrease of 1% and 2%, respectively.
Dramatic depreciation of the Kwacha against the US$ in 2014 and
2015 made this equivalent to decreases of 9% and 23% in US$
terms, respectively. Personnel comprised between 42% and 58%
of the government health budgets between 2011–2017. In 2014,
government health expenditures inclusive and exclusive of person-
nel totalled US$ 690 million and US$ 297 million, respectively.
Routine immunisation programme costs were US$ 52.9 million
in 2014, equivalent to 0.2% of GDP. Gavi funded approximately 20%
of these costs. Immunisation programme expenditures paid for by
the government comprised approximately 6% of government
health expenditures. Vaccine expenditures comprised 1% of gov-
ernment health expenditures excluding personnel (Fig. 3). Per cap-
ita immunisation programme costs were US$ 2.36 in 2011, US$
2.54 in 2014 and projected as US$ 2.91 in 2022. Government
funded vaccine and injection equipment costs per capita will
increase from US$ 0.14 in 2011 to US$ 1.00 in 2022.
Assuming a 5% annual, inflation-adjusted increase in govern-
ment health expenditures during 2017–2022, immunisation pro-
gramme costs are projected to be 5% of total health expenditures
in 2022. When assuming 0% increase in government health expen-
ditures, immunisation costs would account for 10% in 2022.
Considering vaccine costs alone and assuming 5% real increase
in government health expenditures, these will account for 3% in
2022 exclusive personnel. When assuming 0% annual increase until
2022, the proportion is 6%. For vaccine costs to remain at 1% of gov-
ernment health expenditures, excluding human resources, the
nominal budget needs to increase by 30% each year between
2017 and 2022.
4. Discussion
Incremental, annual systems costs of introducing the three new
vaccines were US$ 4.9 million, equivalent to US$ 7.69 per child in
the birth cohort and US$ 0.31 per capita. With a total of 2.8 million
doses delivered, the systems costs per vaccine dose delivered of all
three vaccines were US$ 1.78. The systems costs were US$ 1.33 for
PCV, US$ 2.15 for RV and US$ 3.43 for MSD. Costs of simultaneous
introduction of PCV, RV and MSD in Ghana in 2012 totalled US$
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Fig. 1. Zambia’s co-financing of new vaccines supported by Gavi, 2008–2022 (US$). PCV: Pneumococcal conjugate vaccine, RV: Rotavirus vaccine, MSD: Measles second dose.
Note: The spikes in 2008 and 2013 are due to pentavalent and pneumococcal vaccine introductions, respectively. Less vaccines were supplied in the subsequent years due to
remaining stock from the years of introductions.
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2.42 per dose [34]. As this analysis was part of the EPIC studies, the
methodology was quite similar to the present Zambia study and
differences are likely due to distinct levels of unit costs between
the two countries. A study in Gambia found incremental systems
costs of PCV introduction of US$ 1.90 [35]. The higher costs in
Gambia could be because this was not part of a simultaneous intro-
duction. A study in Rwanda found economic systems costs of intro-
ducing PCV and RV of US$ 0.68 and US$ 0.54 per dose, respectively
[36]. The higher costs in Zambia than Rwanda are especially due to
differences in methods for estimating staff costs. While our esti-
mate was based on economic costing of a sample of health facilities
by the EPIC study, the Rwanda study assumed that it took six
minutes to deliver a dose of vaccine, based on program manager
information.
When including costs of vaccines, annual incremental costs of
the three introductions amounted to US$ 23 per child in the birth
cohort. It led to a cost increase of 38%, resulting in total immunisa-
tion programme costs of US$ 52.9 million in 2014, equivalent to
US$ 102 per penta3 child. This is comparable to US$ 132 per penta3
child in Honduras, where PCV, RV and MSD have also been
introduced [37].
Cold chain investments may be essential for new vaccines, and
have been a major focus of cost studies of earlier new vaccine
introductions [3]. However, in Zambia the new equipment only
Fig. 2. Actual and predicted Government health and immunisation expenditures per capita, 2008–2022. Note: From 2017 onwards, Government health expenditures are
predicted using an assumption of 10% annual, nominal increase, equivalent to approximately 5% in real terms. The exchange rate between the Kwacha and the US$ is assumed
constant at 8.1 between 2015 and 2022.
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represented 1% of incremental costs over time. Hence, while the
‘one-time’ costs are a substantial up-front investment, they are less
important when spread over their expected lifetime.
Government health expenditures have fluctuated since 2008.
Zambia experienced a serious economic situation in 2015. The
annual economic growth rate declined from an average of 7% since
2010 to 3.4% in 2015 [38], partly caused by a drastic drop in the
international copper price, Zambia’s main export earner [39]. It is
consequently challenging to predict whether or by how much real
government health expenditures will increase in coming years.
Moreover, wide fluctuations of the Kwacha increase uncertainty.
The average exchange rate to the US$ was 4.79 Kwacha in 2011.
In 2012, 2013 and 2014, the rates were 5.18, 5.35 and 6.12, respec-
tively [13]. However, in 2015, the average rate was 8.56 and it
reached 10.90 by the end of December, making the Kwacha that
year’s worst performing currency against the US$ [13,38].
Immunisation is projected to comprise 5–10% of government
health expenditures in 2022, compared to 6% in 2014. The propor-
tion depends on the extent real government health expenditures
increases and assuming no further deterioration in the exchange
rate. Even though there are no benchmarks for optimal spending
on immunisation, these proportions must be considered relatively
high. Projected vaccine and injection equipment costs of 3–6% of
non-personnel health spending are also higher proportions than
those reported as potentially challenging in other countries [12,40].
Numerous studies from sub-Saharan Africa have shown sub-
stantial health impacts and cost-effectiveness of PCV, RV and
MSD [41–43]. There is thus little doubt that these vaccines are a
sound investment in population health, but substantial increases
in domestic financing for vaccines are necessary to ensure sustain-
ability. Zambia funded 83% of immunisation programme costs in
2011 and has continued to increase its contribution, showing
strong commitment [6]. Increasing resources to health or
improving efficiency of services can potentially create fiscal space.
However, it is a substantial challenge to achieve reallocations of
the magnitude required for the multiple new vaccines and
increased provisions to health can be expected to be difficult given
the economic context. If increasing provisions to vaccines inadver-
tently crowd out funding of other items, such as transport for
supervision and outreach, this could damage overall immunisation
performance. Hence, all sustainability options require advocacy
and responsive planning to reinforce the focus of government
and partners on ensuring optimal transition.
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